

1 **DOES BARIATRIC SURGERY IMPROVE CARDIAC AUTONOMIC**
2 **MODULATION ASSESSED BY HEART RATE VARIABILITY?**
3 **A SYSTEMATIC REVIEW**

4
5 **BARIATRIC SURGERY AND HEART RATE VARIABILITY**

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

WORD COUNT: 3969

ABSTRACT

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

OBJECTIVES: Our study aimed to explore the influence of Bariatric Surgery (BS) on heart rate (HR) variability (HRV) through a systematic review. **DATA SOURCES:** Manuscripts were selected based on electronic searches of MEDLINE, EMBASE and CINAHL databases from the inception of each database up to year 2020 and followed the PRISMA protocol. Searching of these studies was systematized using the PICOS strategy. **ELIGIBILITY CRITERIA FOR SELECTING STUDIES:** We selected randomized and non-randomized controlled trials and cohorts' prospective studies that reported the influence of BS on HRV. We assessed the quality rating using the Black and Downs questionnaire. **RESULTS:** Following the screening and eligibility stages, 14 studies were included in the review. All studies agreed that BS promotes an increase in parasympathetic HR control and HRV and, a decrease in HR. Yet, the literature does not provide evidence that this outcome was directly caused by the surgical procedure. There is limited evidence to support that patients with type 2 Diabetes Mellitus (TDM2) have greater improvement in HRV as an interim measure, to individuals without. The decrease in insulin resistance was correlated with the increase in HRV in some studies, but, other studies are unsupportive of this outcome. Improvements in two metabolic parameters (e.g., Leptin, NT-proBNP) were connected with a superior increase in HRV. **SUMMARY/CONCLUSION:** This review demonstrated that BS promotes an increase in HRV, indicating improved autonomic control of HR.

Key-words: Bariatric Surgery; Obesity; Heart Rate Variability; Rehabilitation; Cardiovascular Physiology; Metabolic Diseases.

58 INTRODUCTION

59 Cardiovascular activity is partly regulated by afferent and efferent nerves in the
60 subdivisions (sympathetic and parasympathetic) of the autonomic nervous system (ANS)
61 [1-7]. The ANS has the important role of modulating cardiac activity and adapting it on
62 different occasions, through excitatory and inhibitory stimuli [5,8]. These reflexes under
63 normal conditions are modulated with a high degree of precision and speed [3,8-9].

64 HRV is a non-invasive technique to assess cardiac autonomic function via the
65 quantification of the oscillations in milliseconds between consecutive RR-intervals of
66 sinus origin. These values are applied in mathematical formulas that generate HRV
67 indices. [10-12]. HRV is considered one of the most reliable and robust techniques for
68 assessing the autonomic balance [9,13-14]. Changes in HRV are applied as a sensitive
69 and early indicator of impairment in physiological homeostasis [15]. High HRV is a sign
70 of good ANS adaptation and characterizes a healthy individual, with efficient autonomic
71 regulation. Conversely, low HRV is frequently a sign of incapacity and insufficient
72 adaptation of the ANS, manifesting a physiological malfunction [12].

73 Part of the cardiovascular burden promoted by excess body mass involve changes
74 in autonomic nervous system (ANS) control [16-17]. In obese individuals, HRV is
75 reduced, which is produced by a reduction of vagal (parasympathetic) flow and an
76 increase in sympathetic drive [16,18-19]. A reduced HRV is associated with alterations
77 in cardiac function (e.g., increases in HR and blood pressure) and structure (e.g., left
78 ventricular hypertrophy, left atrial enlargement), increasing the risk of cardiovascular
79 diseases and events (e.g., heart failure, arrhythmias, stroke, and myocardial infarction)
80 [16,17,18].

81 The cardiovascular disturbance triggered by autonomic dysfunction in obesity
82 highlights the importance of therapeutics targeting autonomic function during obesity
83 management [20,21]. Bariatric Surgery (BS) is the gold standard treatment for weight

84 loss in persons with severe obesity ($BMI \geq 35 \text{ kg/m}^2$) [22] in a short period and, with a
85 long-term durability [23-27]. The American Society for Metabolic and Bariatric Surgery
86 (ASMBS) reported an annual and upward growth of BS [28] procedures, as other
87 approaches (e.g., drugs, restrictive diets), have been unsuccessful in reducing weight
88 [29,30], and maintaining this loss over an extensive period of time [31,32].

89 The research by Karason *et al.* [33] was ground-breaking in evaluating the
90 metabolic effects produced by BS in the restoration of HRV. Since then, other studies
91 have determined to investigate the effects of different types of BS (e.g. Roux-en-Y,
92 Vertical Sleeve, Biliopancreatic Diversion, Duodenal Switch and Adjustable Gastric
93 Band) on restoring autonomic control of HR [34-47]. In a corresponding way, recent
94 experiments have correlated the improvement of HRV with other physiological variables
95 that have implications for the morbidity profile of obesity (e.g., Leptin, GLP-1, NT-Pro-
96 BNP, Insulin Resistance) as they have an affinity with the cardiovascular functioning
97 [34,36-42].

98 Nevertheless, thus far, no study has anticipated investigating the techniques
99 needed to access HRV after BS in primary studies and, what are the effects of different
100 types of BS techniques on HRV? It is unclear if there are major changes in HRV after BS
101 in populations with specific characteristics (e.g., type 2 Diabetes Mellitus (TDM2) and
102 insulin resistance (IR)). Additionally, no article explores and accumulates information
103 regarding the modification of metabolic parameters that were correlated with the
104 improvement of HRV.

105 So, we performed the first systematic review to assess the effects of BS on HRV
106 with the aim of investigating:

- 107 1. the HRV analysis methods performed in primary studies;
- 108 2. the effects of different types of BS on HRV; and,

109 3. the implication of metabolic conditions (e.g., IR and TDM2) and metabolic
110 parameters (GLP-1, Leptin, NT-proBNP) that were previously related to HRV.

111 **METHODS**

112 This review was conducted via a systematized search, from June 2020 to December
113 2020. The following databases were accessed: EMBASE, MEDLINE (via PubMed) and
114 CINAHL. The review was performed according to the protocol Preferred Reporting Items
115 for Systematic Reviews and Meta-Analyzes (PRISMA) [48]. The protocol for this review
116 was published on International Prospective Register of Systematic Reviews
117 (PROSPERO) under Protocol registration number CRD42020194156.

118 **Search strategy**

119 The search of the articles was performed via the keywords obtained by the Medical
120 Subject Headings (MeSH) and others search terms. The search and selection of the studies
121 were completed using the Population (P) Intervention (I) Comparison (C) Outcome (O)
122 Study Design (S) (PICOS) strategy. The search strategy was defined with MeSH and
123 search terms allocated in each category according to its search characteristic: P – Obesity,
124 I – Bariatric Surgery, C – Non-surgical procedure, O - Heart rate variability, S –
125 Interventional Studies (Randomized trials, non-randomized controlled trials) and
126 Observational studies (cohorts, prospective and longitudinal studies).

127 The following search terms were applied: “Obesity” AND “Bariatric Surgery” OR
128 “Gastric Bypass” OR “Gastric Banding” OR “Gastric Sleeve” OR “Duodenal Switch”
129 AND “Heart Rate Variability” OR “Autonomic Nervous System” OR “Autonomic
130 Dysfunction” OR “Sympathetic Nervous System” OR “Parasympathetic Nervous
131 System” OR “Vagal Nerve” in their titles and/or in their abstracts.

132

133 **Screening and Study Eligibility Criteria**

134 The returned studies were screened by applying search criteria in the databases,
135 via the following filters: studies undertaken from the inception of each database until year

136 2020 and research performed on human subjects. In sequence, the studies identified in
137 the databases were screened by reading their title and abstract.

138 The final selection phase for inclusion of the articles was undertaken by reading
139 the articles in full (eligibility), performed by two independent researchers (CJRB and
140 YMMP). If there was discrepancy about the inclusion of a particular article, an extra
141 reviewer (VEV) was consulted for a final choice. The eligibility criteria for the studies
142 are determined below:

143 Patients (subjects)

144 Adults, male and female (between 18 and 70 years of age) with body mass index
145 (BMI) $\geq 30 \text{ kg / m}^2$ and that undertook a BS intervention were selected for inclusion.

146 Intervention

147 We considered several types of bariatric surgery: “Roux-en-Y gastric by-pass
148 (RGB)”, “Vertical Sleeve Gastrectomy (VSG)”, “Biliopancreatic Diversion (BPD)”,
149 “BPD with a Duodenal Switch (BPD- DS)” and “Adjustable Gastric Band (AGB)”.
150 Surgical procedures could include a form of open surgery (laparotomy) and the minimally
151 invasive (laparoscopic) procedures.

152 Control

153 When applicable the control group was defined as any group that was unable to perform
154 BS. In the Braga et al. [34] study, the control group received pharmacological treatment.
155 Whereas, in the studies by Lips et al. [40], Bobbioni-Harsch et al. [42] and Nault et al.
156 [45] the participants control was only followed for the same period, but no treatment
157 was applied. For the other studies, individuals were their own controls before and after
158 BS.

159 160 Study Design

161 Interventional studies (randomized and non-randomized controlled trials), and
162 observational studies (prospective cohort studies).

163 **Data Analysis**

164 The main consequence was the deviations produced in the HRV and HR (beats
165 per minute) by the surgical procedure.

166 For the analysis of cardiac autonomic control, we measured linear indices (time
167 and frequency domain) and the nonlinear indices of HRV [49].

168 Time domain: RMSSD = square root of the mean of the square of the differences between
169 adjacent normal RR intervals; SDNN = standard deviation of all normal RR intervals
170 recorded in a time interval, expressed in ms; SDANN = the standard deviation of averaged
171 RR intervals over a 5-minute period; pNN50 = percentage of adjacent RR intervals with
172 a difference in duration greater than 50ms); NN50 = number of NN intervals differing by
173 more than 50 ms. Frequency domain: HF = high frequency component of power spectral
174 analysis with variation from 0.15 Hz to 0.44 Hz in absolute units (ms^2) and normalized
175 units (n.u.) (vagal component); LF = low frequency component with variation between
176 0.04 and 0.15 Hz in absolute units (ms^2) and normalized units (n.u.) (sympathetic drive);
177 LF/HF = relationship between low and high frequency components (sympathetic/vagal
178 balance). Linear (geometric indexes): HRVi = triangular index calculated from the total
179 number of all NN intervals divided by the height of the histogram of all NN intervals.
180 TINN = Triangular Interpolation of NN intervals histogram. Poincaré-plot indexes: SD1
181 = standard deviation of the instantaneous variability of the beat-to-beat heart rate; SD2 =
182 standard deviation of long-term continuous RR interval variability; SD1/SD2 = The ratio
183 of SD1 over SD2 (balance of parasympathetic nervous system (PNS) to sympathetic
184 nervous system (SNS) - PNS/SNS tone); Nonlinear (complexity indexes): SampEn =

185 Sample Entropy [50,51]; DFA = Detrended fluctuation (fractal) analysis of RR intervals
186 [52,53].

187 The documents that completed the entire analytical process and were suitable for
188 this review had their data extracted in a table with a description of the characteristics of
189 the study population, intervention and outcomes (Table 1).

190 **Quality Rating**

191 The Downs and Black [54] questionnaire was performed to assess the value of the
192 studies. The evaluators independently judged the quality of the studies using the checklist
193 and then any discrepancies in the classifications were discussed to arrive at a final score
194 for each study. This tool is divided into five domains: "report of articles", "external
195 validity", "bias", "confounding variables" and "statistical power" (Table 2). We selected
196 this tool as it can be applied to interventional and observational studies [54]. Two different
197 members of the research team (CJRB and YMMP) studied each article in duplicate.

198 **RESULTS**

199 **Study Selection**

200 A total of 392 studies were identified through the searches in all the five databases.
201 Following removal of duplicates ($n=85$), 307 publications were screened for inclusion.
202 Of these, 279 records were excluded after reviewing their title and/or abstract. The
203 remaining 28 papers were selected for full text reading and seven were excluded because
204 the characteristics of intervention were unclear; five articles used inadequate
205 measurement methods and two were excluded because of an unspecific procedure of BS.
206 Finally, 14 studies were included in the systematic review. The search process and
207 selection steps are illustrated in the Flow Diagram of the PRISMA protocol (Figure 1).

208 Figure 1. Flow diagram of the Prisma protocol with search process and selection
209 steps.

210 Description of the features of the study population, intervention and outcomes is
211 illustrated in Table 1.

212 **Quality Assessment**

213 The evaluation of the Downs and Black Checklist for Quality Assessment is stated
214 in Table 2.

215 The percentage agreement between the two researchers who assessed the quality
216 of the 14 studies was 92.85%. The quality ratings of the included studies are revealed in
217 Table 2. The ratings ranged from 17 to 23 (out of a possible 27). Throughout the analysis
218 was included ten prospective cohort studies and two non-randomized controlled trials. No
219 study has attempted to blind patients to the intervention received or blind evaluators who
220 assessed primary outcomes and, so, the results should be considered with these
221 methodological limitations in mind.

222 **Assessment of HRV**

223 HRV measurements were performed within 7 days and 12 months after the BS
224 procedure. Right now, the studies demonstrated heterogeneity throughout the periods
225 when HRV was measured after performing the BS procedure. So, there is no way to assess
226 when changes in HRV occur most prevalently after the BS procedure, considering the
227 discrepancies between the intervals at which HRV was computed.

228 Only one study measured HRV before (7 days) metabolic changes occurred and,
229 thus, there is no evidence to support that the effects produced by HRV are directly induced
230 by the surgical procedure.

231 HRV was assessed in a comprehensive manner using five studies through Holter
232 ECG, [37,41,43,44,45] followed by the Electrocardiogram (four studies) [35,38,39,40].
233 One study applied Plethysmography [34], another study enforced the Polar RS800CX HR
234 monitor [46]. Only one study used the VariaCardio T4 device [47], another study assessed
235 HRV by Echocardiography [42]. Lastly, one study did not report the apparatus used to
236 collect HRV whatsoever [36].

237 Seven studies were performed during the rest period considering a recording
238 between 5 to 30 minutes of HRV duration [34,35,38,39,40,43,46]. A further five studies
239 [37,41,42,44,45] performed the recording of HRV for 24 hours, and two studies did not
240 report the recording time [36,47]. Altogether, 9 studies cited the recommendations of the
241 Task Force of the European Society of Cardiology and the North American Society of
242 Pacing and Electrophysiology (1996) as a reference for studying HRV, but, only one
243 study described the filtering methods employed in the recorded RR time-series.

244 One or more parameters in the time domain were applied in twelve studies and
245 parameters in the frequency domain in six studies. In five studies, HRV parameters were
246 enforced in the domain of time and frequency. Only two studies applied non-linear HRV
247 parameters.

248 The most frequently enforced HRV parameters in the time domain were RMSSD
249 (eleven studies) and SDNN (eleven studies). The frequency domain parameters most
250 frequently applied were HF potency in absolute or normalized units (six studies), LF
251 potency in absolute or normalized units (six studies) and the LF/HF ratio (six studies).
252 The most widely used non-linear index was Sample Entropy (two studies). Poincaré-plot
253 indices (SD1, SD2 and SD1/SD2) were enforced in three studies. The deviations in the
254 follow-up period after BS are illustrated in Table 3. HR (bpm) was recorded in ten studies.
255 All of these verified that there was a reduction in HR after the completion of the BS.

256 **Bariatric Procedures**

257 Generally, all combined BS (e.g., RGB and AGB, and RGB and SVG) or isolated
258 (e.g., RYGB, SVG, BPD-DS) surgical methods employed in the experiments were
259 effective in improving HRV following weight loss (Table 3).

260 **Diabetes Mellitus and Insulin Resistance**

261 Despite limited evidence, studies by Lips *et al.* [40] and Casellini *et al.* [36]
262 identified that the increase in HRV arises earlier in patients with TDM2 when compared
263 to patients without TDM2 in the same cohort, occurring at 3 weeks and 12 weeks,
264 respectively.

265 Amongst the selected studies, five performed correlations between decreased
266 insulin resistance and glucose levels with increases in HRV. Studies by Maser *et al.* [39],
267 Perugini *et al.* [41] and Bobbioni-Harsch *et al.* [42] found no connection between the
268 reduction in insulin resistance levels and the improvement of autonomic activity. In
269 contrast, two studies demonstrated a positive correlation in the decrease in insulin
270 resistance with an increase in HRV [38, 40].

271 **Biomarkers (Leptin, GLP-1, NT-proBNP)**

272 Only one of the two studies [40,42] that assessed Leptin identified a significant
273 reduction at 3 ($p<0.05$) and 12 ($p=0.003$) months after BS; for this hormone.
274 Accompanying this, the decrease in Leptin established a positive correlation with an
275 increase in HRV [42]. Amongst the studies included, only Gandolfini *et al.* [37] assessed
276 the quantities of NT-proBNP. An increase in NT-proBNP was observed within the
277 physiological range after BS and was positively correlated with HRV optimization [37].
278 Five of the thirteen studies stated an increase in GLP-1 secretion after BS, but all of them
279 observed that this increase was unrelated to enhancements in HRV parameters [34,36-
280 38,40].

281 **DISCUSSION**

282 This is the first systematic review that intended to explore the influence of BS and
283 associated factors on HRV. As stated herein, it was possible to observe that:

284 1) the studies present heterogeneity regarding the HRV measurement intervals
285 during follow-up after BS; 2) the equipment and duration of HRV recordings are different
286 between studies; 3) there was an increase in parasympathetic HR control and HRV and,
287 a decrease in HR in all BS methods undertaken; 4) the literature does not provide evidence
288 that this effect was directly caused by the surgical procedure; 5) few studies have
289 demonstrated that BS encouraged an earlier and more evident restoration of cardiac
290 autonomic control in patients with TDM2; 6) the decrease in insulin resistance was
291 correlated with the increase in HRV in some studies, but, other studies are unresponsive
292 of these outcomes; 7) improvements in metabolic parameters (e.g., Leptin, NT-proBNP)
293 were positively correlated with an increase in HRV.

294 In obese individuals, the sensitivity of adrenergic receptors is compromised,
295 producing autonomic imbalance wherein vagal tone is reduced and sympathetic activity
296 is increased. The increase in sympathetic tone mitigates cardiac autonomic modulation
297 and decreases HRV [42]. The large-scale production of pro-inflammatory cytokines
298 produced by excess adipose tissue is partly responsible for the impairment of the ANS in
299 patients with obesity [53]. It has been demonstrated that the magnitude of inflammation
300 assessed by biomarkers (e.g., fibrinogen, C-reactive protein, IL-6) causes impairment in
301 vagal efferent flow and, so, is responsible for HRV decrease [54-55]. These effects were
302 observed in young people [56], as well as in older populations with obesity [53].

303 Thus, weight loss occasioned after BS originates an increase in the vagal efferent
304 flow, causing greater parasympathetic conduction and promoting an increase in HRV
305 [41]. These effects are sturdier in obese persons who have had a weight reduction of

306 approximately 10% [59]. In the treatment of obesity, weight loss is identified as the main
307 cause of increased parasympathetic HR modulation [60-63] and decreased sympathetic
308 modulation [60-61,63], since the opposite effect is observed with the gain of adipose
309 tissue [63-64].

310 In our review, studies that controlled the effect of BS with non-surgical treatments
311 did not result in significant weight loss and, consequently, did not show changes in HRV
312 patterns. Despite this, other evidence has already elucidated that there is an increase in
313 HRV in different types of non-surgical strategies that culminated in weight loss. Calorific
314 restriction [59,61,66] combined or not with physical exercise [60,62], intermittent fasting
315 [65-66] pharmacological use of absorption inhibitors [67], and even by less conventional
316 methods such as electrical stimulation C1-C2 have reported changes in HRV after causing
317 weight reduction [69]. These findings reinforce the evidence that the effect on HRV is
318 totally dependent on weight loss and independent of the intervention type [59]. Yet, these
319 interventions have been ineffective in reducing weight [29, 30], and maintaining this loss
320 over an extensive period of time [31,32].

321 **HRV Indexes**

322 The majority of studies that analyzed linear indices displayed changes in HRV
323 between 6 and 12 months after the bariatric procedure. Nonetheless, we must emphasize
324 that these results can be offered more frequently since a smaller number of studies made
325 other evaluations (in days and weeks) between six months.

326 A study directed by Alam *et al.* [43] suggested that autonomic changes could be more
327 sensitive to identification in nonlinear indices of complexity, assuming that these
328 components have experienced prior changes compared to linear indices. Throughout the
329 results of this study, the Sample Entropy and the Detrended fluctuation analysis (DFA)
330 established positive changes in the first month after BS. Still, the experimentation by

331 Ibacache *et al.* [46] similarly applied non-linear or complexity methods in the analysis
332 and revealed no change in Sample Entropy in one and three months after the BS
333 procedure.

334 The sympatho-vagal balance index that was supplementary in some studies,
335 considered by the LF/HF HRV ratio, has been frequently demonstrated to be theoretically
336 flawed and empirically unsupported. Though there are many criticisms of this measure,
337 the most serious concern is that LF does not guide sympathetic modulation and so there
338 is a lack of rationale (and/or convincing evidence) that its benefit regarding the HF
339 component would index relative strength of vagal and sympathetic signaling [70-76].

340 The primary studies have an important restriction in that the time measurements are
341 recorded after BS, assuming that the collection dates have a large time interval (e.g., 1 to
342 3 months) amid each measurement. Only Wu *et al.* [38] performed a more detailed
343 follow-up after BS, namely, performed measurements in days, weeks and months after
344 BS. Hence, monitoring with shorter intervals between HRV recordings could better
345 categorize the change in autonomic behavior following BS. Hitherto, only two studies
346 have completed nonlinear assessments and so should be further explored in subsequent
347 investigations.

348 All studies that assessed the HR established a decrease after BS. These reductions
349 in HR can be elucidated by the improvement in cardiovascular activity after BS. We
350 emphasize that these effects are somewhat because of increased cholinergic activity on
351 the heart and a partial blockage of adrenergic activity [77]. Relating to this, a
352 transformation of the heart occurs, wherein there is a reversal of the ventricular mass [78-
353 80] and a surge in the cardiovascular ejection fraction [79], lessening the requirement of
354 the cardiac pumping frequency. Therefore, this decrease in HR is partially independent
355 of the increase in HRV. Besides the stated issues, other metabolic factors are related to

356 the decrease in HR. In Gandolfini *et al.* [37], a correlation was revealed between HR
357 optimization and the obtainability of glucose, insulin resistance and GLP-1.

358 With the measurement of time after BS, in patients with TDM2, autonomic
359 optimization was identified in a shorter period. Within three weeks, an increase in HRV
360 was identified in the RMSSD, SD1, SD2 and SD1/SD2 indices [40]. In individuals
361 without TDM2 who received RYGB, changes were only achieved in measurements taken
362 after 3 months of surgery [40]. Casellini *et al.* [36] further identified this effect, in the
363 comparison between groups of non-diabetics, pre-diabetics and those with TDM2; the
364 final group being favored by BS. At 12 weeks following the intervention, a significant
365 increase was identified in the SDNN ($p < 0.005$) and RMSSD ($p < 0.001$) indices of
366 TDM2. For the group with pre-DM, deviations were only achieved in the 24th week in the
367 RMSSD index ($p < 0.05$) and in non-diabetics, no changes were attained. This can be
368 clarified by the positive correlation in the decrease in insulin resistance and a pronounced
369 increase in HRV in individuals undergoing BS [38,40].

370 Whilst this is an interesting principle, only these two studies confirmed these
371 results and, so, further evidence is required to provide greater support for these
372 conclusions.

373 **Biomarkers**

374 Further aspects responsible for the development of complications in obese
375 individuals established improved parameters after BS, which can have direct or indirect
376 effect on HRV.

377 Amongst which, the N-terminal pro b-type natriuretic peptide (NT-proBNP) and
378 Leptin, correlated with the progression of HRV. The increase in HR autonomic control
379 sympathetic drive, in obese persons, is also linked to elevated Leptin levels. Lately, it has
380 been recognized that Leptin is capable of directly stimulating hypothalamic neurons

381 involved in the sympathetic activation network [81,82]. Similarly, its decrease triggered
382 a diminution in sympathetic activity and, so an increase in HRV [42]. As this hormone is
383 created in adipose cells, individuals with excess adipose tissue have a higher production
384 of Leptin [82,84].

385 An increased in NT-proBNP demonstrated a significant correlation with improved
386 HRV [85-86]. This biomarker can be adapted to classifying the degree of survival of
387 patients with heart failure, in which values >6000mg/dl represent a severe level of disease
388 and a reduced survival during about 90 days of evaluation [87]. In contrast, the observed
389 improvement varied within the range of 200mg/dl. In this case, these effects are connected
390 with an improvement in the sinus response from the properties of NT-proBNP, producing
391 inhibition of adrenergic activity [77] and increased HRV [37].

392 In contrast, Glucagon-like peptide-1 (GLP-1) can be considered as independent
393 factors, as they were unable to display correlations with HRV restoration. Insulin
394 resistance remains a variable that has contentious results, since some studies [38, 40]
395 correlate with increased HRV and others do not [39, 41, 42].

396 **Perspectives**

397 We consider BS as an effective metabolic intervention, wherein besides reducing
398 weight (and therefore BMI), it is effective in the remission of some conditions (e.g.,
399 TDM2, Arterial hypertension, Sleep apnea) [37], but reliant on *several* metabolic
400 characteristics enhanced by this weight reduction [36,37,39,41,42].

401 New studies can categorize the effects of BS in patients with specific diseases. We
402 emphasize that this approach is proposed chiefly on the characteristics of the study
403 population, given that some experiments have patients with different health conditions
404 (e.g., arterial hypertension, Sleep apnea).

405 We recommend that HRV can be employed to evaluate cardiac autonomic control
406 restoration after BS in obese persons. The relevance of employing HRV as an indicator
407 of risk factors for evaluating and identifying health impairments related to autonomic
408 function is reassuring. Our assessment elucidates the contribution of HRV analysis in
409 detecting health changes, presenting itself as an efficient complementary assessment in
410 the identification of health outcomes of obese patients undergoing BS. Hence, it is a tool
411 of great clinical importance in the prognosis of BS.

412 **CONCLUSION**

413 In summary, we detailed suitable references that assessed HRV in subjects
414 submitted to BS. The primary studies are unclear in the way wherein HRV data are
415 processed. Despite this, all studies have revealed an increase in HRV after the BS
416 procedure irrespective of the surgical method employed. There is evidence that patients
417 with TDM2 may experience a more significant increase in HRV following surgery.
418 Leptin and NT-pro-BNP are hormones that exhibit a correlation with the improvement of
419 HRV after BS.

420

421

422

423

REFERENCES

424

425

426 1. Catai AM, Pastre CM, Godoy MF, et al. Heart rate variability: are you using it
427 properly? Standardisation checklist of procedures. *Braz J Phys Ther.* 2020;24(2):91-102.

428 doi: 10.1016/j.bjpt.2019.02.006

429 2. Besson C, Saudabe M, Gremeaux V, et al. Heart rate variability: methods,
430 limitations and clinical examples. *Rev Med Suisse.* 2020;16(701):1432-1437.

431 3. Kim HG, Cheon EJ, Bai DS, Lee YH, Koo BH. Stress and Heart Rate Variability:
432 A Meta-Analysis and Review of the Literature. *Psychiatry Investig.* 2018;15(3):235-245.

433 doi: 10.30773/pi.2017.08.17

434 4. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms.
435 *Front Public Health.* 2017;5:258. doi: 10.3389/fpubh.2017.00258

436 5. Billman GE, Huikuri HV, Sacha J, Trimmel K. *Front. Physiol.* 2015;6:55. Doi:
437 10.3389/fphys.2015.00055

438 6. Billman GE. Heart rate variability – a historical perspective. *Front. Physiol.*
439 2011;2:86. doi: 10.3389/fphys.2011.00086

440 7. Cygankiewicz I, Zareba W. Heart rate variability. *Handb Clin Neurol.*
441 2013;117:379-393. doi: 10.1016/B978-0-444-53491-0.00031-6.

442 8. Mitchell JH, Victor RG. Neural control of the cardiovascular system: insights
443 from muscle sympathetic nerve recordings in humans. *Med Sci Sports Exerc.*
444 1996;28(10):60-69. Doi: 10.1097/00005768-199610000-00036

445 9. Singh N, Moneghetti KJ, Christle JW, et al. Heart Rate Variability: An Old Metric
446 with New Meaning in the Era of using mHealth Technologies for Health and Exercise
447 Training Guidance. Part One: Physiology and Methods. *Arrhythm Electrophysiol Rev.*
448 2018;7(3):193-198. doi: 10.15420/aer.2018.27.2

- 449 10. Triggiani AI, Valenzano A, Trimigno V. et al. Heart rate variability reduction is
450 related to a high amount of visceral adiposity in healthy young women. Plos One
451 2019;14(9):e0223058. <https://doi.org/10.1371/journal.pone.0223058>
- 452 11. Laborde S, Mosley E, Thayer JF. Heart Rate Variability and Cardiac Vagal Tone
453 in Psychophysiological Research – Recommendations for Experiment Planning, Data
454 Analysis, and Data Reporting. *Frontiers in Psychology* 2017;8:213.
455 DOI:10.3389/fpsyg.2017.00213
- 456 12. Vanderlei LCM, Pastre CM, Hoshi RA, Carvalho TD, Godoy MF. Noções básicas
457 de variabilidade da frequência cardíaca e sua aplicabilidade clínica. *Rev Bras Cir*
458 *Cardiovasc.* 2009;24(2):205-217. <http://dx.doi.org/10.1590/S0102-76382009000200018>
- 459 13. Hayano J, Yuda E. Pitfalls of assessment of autonomic function by heart rate
460 variability. *J Physiol Anthropol.* 2019;38:3. doi: 10.1186/s40101-019-0193-2
- 461 14. Zygmunt A, Stanczyk J. Methods of evaluation of autonomic nervous system function.
462 *Arch Med Sci.* 2010;6(1):11-18. doi: 10.5114/aoms.2010.13500
- 463 15. Young HA, Benton D. Heart-rate variability: a biomarker to study the influence of
464 nutrition on physiological and psychological health?. *Behav Pharmacol.*
465 2018;29(2):140-151. doi: 10.1097/FBP.0000000000000383
- 466 16. Yadav RL, Yadav PK, Yadav LK, Agrawal L, Sah S, Islam N. Association Between
467 Obesity and Heart Rate Variability Indices: An Intuition Toward Cardiac Autonomic
468 Alteration - A Risk of CVD. *Diabetes Metab Syndr Obes.* 2017;10:57-64.
469 10.2147/DMSO.S123935
- 470 17. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling obesity. *Physiol. Rev*
471 2008;88(2):389-419. doi:10.1152/physrev.00017.2007.
- 472 18. Willians SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac
473 Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A

- 474 Narrative Review. Diabetes Therapy 2019;10(6):1995-2021.
475 <https://doi.org/10.1007/s13300-019-00705-z>.
- 476 19. Santana MDR, Kliszczewicz B, Vanderlei FM. et al. Autonomic responses
477 induced by aerobic submaximal exercise in obese and overweight adolescents. *Cardiol.*
478 *Young* 2019;29(2):169-173. Doi: <https://doi.org/10.1017/S1047951118002007>
- 479 20. Ward ZJ, Bleich SN, Cradock AL. et al. Projected U.S. State-Level Prevalence of
480 Adult Obesity and Severe Obesity. *N Engl J Med* 2019; 381:2440-2450. doi:
481 10.1056/NEJMsa1909301
- 482 21. Dias PC, Henriques P, Anjos LA, Burlandy L. Obesity and public policies: the
483 Brazilian government's definitions and strategies. *Cadernos de Saúde Pública*
484 2017;33(7):e00006016. <https://doi.org/10.1590/0102-311x00006016>.
- 485 22. O'Brien PE. Bariatric Surgery: Mechanisms, Indications and Outcomes. *J*
486 *Gastroenterol Hepatol.* 2010;25(8)1358-65. doi: 10.1111/j.1440-1746.2010.06391.x.
- 487 23. David LA, Sijercic I, Cassin SE. Preoperative and post-operative psychosocial
488 interventions for bariatric surgery patients: A systematic review. *Obesity Reviews*
489 2020;21(4):e12926. doi: 10.1111/obr.12926.
- 490 24. National Institute for Health and Clinical Excellence. Obesity: Guidance on the
491 prevention, identification, assessment, and management of overweight and obesity in
492 adults and children (NICE clinical guideline 43). London: National Institute for Health
493 and Clinical Excellence;2006:1-858
- 494 25. Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity.
495 *Cochrane Database Syst Rev.* 2005;19(4):CD003641. doi:
496 10.1002/14651858.CD003641.pub2
- 497 26. Buchwald H, Avidor Y, Braunwald R. et al. Bariatric surgery: a systematic review
498 and meta-analysis. *Jama-J Am Med Assoc.* 2004;292(14): 1724-1737. doi:
499 10.1001/jama.292.14.1724.

- 500 27. Reoch J, Mottillo S, Shimony A. et al. Safety of laparoscopic vs open bariatric
501 sugery: A systematic Review and Meta-analysis. JAMA Surgery 2011;146(11):1314-
502 1322. doi:10.1001/archsurg.2011.270
- 503 28. ASMBS. American Society for Metabolic and Bariatric Surgery. Estimate of
504 Bariatric Surgery Numbers, 2011-2018. [https://asmbs.org/resources/estimate-of-](https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers)
505 [bariatric-surgery-numbers](https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers)
- 506 29. Faller ALK. Impact of Intermittent Fasting on Body Weight in Overweight and
507 Obese Individuals. Rev Assoc Med Bras. 2020; 15;66(2):222-226.
508 <http://dx.doi.org/10.1590/1806-9282.66.2.237>
- 509 30. Pellegrini M, Cioffi I, Evangelista A. et al. Effects of time-restricted feeding on
510 body weight and metabolism. A systematic review and meta-analysis. Reviews in
511 Endocrine and Metabolic Disorders 2020;21;17-33. [https://doi.org/10.1007/s11154-020-](https://doi.org/10.1007/s11154-020-09542-z)
512 [09542-z](https://doi.org/10.1007/s11154-020-09542-z).
- 513 31. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of
514 Obesity. Medical Clinics of North America. 2018;102(1):183-197.
515 <https://doi.org/10.1016/j.mcna.2017.08.012>
- 516 32. Lowe MR, Butryn ML, Thomas JG, Coletta M. Meal replacements, reduced
517 energy density eating and weight loss maintenance in primary care patients: A
518 randomized controlled trial. Obesity 2014;22(1):94-100. doi:10.1002/oby.20582.
- 519 33. Karason K, Molgaard H, Wikstrand J, Sjöström L. Heart rate variability in obesity
520 and the effect of weight loss. Am J Cardiol. 1999;83:1242-1247.
- 521 34. Braga TG, Souza MGC, Maranhão PA. et al. Evaluation of Heart Rate Variability
522 and Endothelial Function 3 Months After Bariatric Surgery. Obesity Surgery
523 2020;30(6):2450-2453. doi: 10.1007/s11695-020-04397-4.

- 524 35. Lucas CMS, Zaniqueli D, Alvim RO, Miguel GPS, Mill JG. Longitudinal study
525 of the sympathovagal balance in women submitted to bariatric surgery. *An Acad Bras*
526 *Ciênc.* 2020;92(1):01-09. Doi: 10.1590/0001-3765202020181184
- 527 36. Casellini CM, Parson HK, Hodges K. et al. Bariatric Surgery Restores Cardiac
528 and Sudomotor Autonomic C-Fiber Dysfunction Towards Normal in Obese Subjects
529 With Type 2 Diabetes. *Plos One* 2016; 11(5):e0154211. doi:
530 10.1371/journal.pone.0154211.
- 531 37. Gandolfini MP, Coupaye M, Bouaziz E. et al. Cardiovascular Changes After
532 Gastric Bypass Surgery: Involvement of Increased Secretions of Glucagon-Like Peptide-
533 1 and Brain Natriuretic Peptide. *Obesity Surgery* 2015;25:1933-1939. doi:
534 10.1007/s11695-015-1643-5
- 535 38. Wu JM, Yue HJ, Lai HS, Yang PJ, Lin MT, Laib F. Improvement of heart rate
536 variability after decreased insulin resistance after sleeve gastrectomy for morbidly obesity
537 patients. *Surg Obes Relat Dis.* 2015;11(3):557-563. doi: 10.1016/j.soard.2014.09.011
- 538 39. Maser RE, Lenhard MJ, Peters MB, Irgau I, Wynn GM. Effects of Surgically
539 Induced Weight Loss by Roux-en-Y Gastric Bypass on Cardiovascular Autonomic Nerve
540 Function. *Surg Obes Relat Dis.* 2013;9(2):221-226. doi: 10.1016/j.soard.2011.11.014.
- 541 40. Lips MA, Groot GH, Kam MD. et al. Autonomic nervous system activity in
542 diabetic and healthy obese female subjects and the effect of distinct weight loss strategies.
543 *European Journal of Endocrinology* 2013;169:383-390. Doi: 10.1530/EJE-13-0506
- 544 41. Perugini RA, Li Y, Rosenthal L, Gallagher-Dorval K, Kelly JJ, Czerniach DR.
545 Reduced Heart Rate Variability Correlates With Insulin Resistance but Not With
546 Measures of Obesity in Population Undergoing Laparoscopic Roux-en-Y Gastric Bypass.
547 *Surg Obes Relat Dis.* 2010;6(3):237-41. doi: 10.1016/j.soard.2009.09.012.

- 548 42. Bobbioni-Harsch E, Sztajzel J, Barthassat V. et al. Independent Evolution of Heart
549 Autonomic Function and Insulin Sensitivity During Weight Loss. *Obesity*
550 2009;17(2):247-253. doi: 10.1038/oby.2008.532
- 551 43. Alam I, Lewis MJ, Lewis KE, Stephens JW, Baxter JN. Influence of bariatric
552 surgery on indices of cardiac autonomic control. *Autonomic Neuroscience: Basic and*
553 *Clinical* 2009;151(2):168-173. doi: 10.1016/j.autneu.2009.08.007.
- 554 44. Machado MB, Velasco IT, Scalabrini-Neto A. Gastric Bypass and Cardiac
555 Autonomic Activity: Influence of Gender and Age. *Obesity Surgery* 2009;19:332-338.
556 Doi: 10.1007/s11695-008-9665-x
- 557 45. Nault I, Nadreau E, Paquet C. et al. Impact of Bariatric Surgery--Induced Weight
558 Loss on Heart Rate Variability. *Metabolism*. 2007;56(10):1425-1430. Doi:
559 10.1016/j.metabol.2007.06.006.
- 560 46. Ibacache P, Cárcamo P, Miranda C, Bottinelli A, Guzmán J, Martínez-Rosales E,
561 Artero EG, et al. Improvements in Heart Rate Variability in Women with Obesity: Short-
562 term Effects of Sleeve Gastrectomy. *Obes Surg*. 2020;30(10):4038-4045. Doi:
563 10.1007/s11695-020-04721-y
- 564 47. Kokkinos A, Alexiadou K, Liaskos C, Argyrakopoulou G, Balla I, Tentolouris N,
565 et al. Improvement in Cardiovascular Indices After Roux-en-Y Gastric Bypass or Sleeve
566 Gastrectomy for Morbid Obesity. *Obes Surg*. 2013;23(1):31-38. Doi: 10.1007/s11695-
567 012-0743-8.
- 568 48. Moher D, Liberati A, Tetzlaff J, Altman DG; Prisma Group. Preferred reporting
569 items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS*
570 *Medicine* 2009;6(7):01-06. <https://doi.org/10.1371/journal.pmed.1000097>
- 571 49. Camm AJ, Malik M, Bigger JT. et al. Heart rate variability: standards of
572 measurement, physiological interpretation and clinical use. Task Force of the European

- 573 Society of Cardiology and the North American Society of Pacing and Electrophysiology.
574 *Circulation* 1996;93(5):1043-65.
- 575 50. Zhang D, She J, Zhang Z, Yu M. Effects of acute hypoxia on heart rate variability,
576 samples entropy and cardiorespiratory phase synchronization. *Biomed Eng Online*
577 2014;13:73. doi: 10.1186/1475-925X-13-73.
- 578 51. Richman JS, Moorman JR. Physiological time-series analysis using approximate
579 entropy and sample entropy. *Am J Physiol Heart Circ Physiol*. 2000;278(6):H2039-49.
580 doi: 10.1152/ajpheart.2000.278.6.H2039
- 581 52. Bryce RM, Sprague KB. Revisiting detrended fluctuation analysis. *Scientific*
582 *Reports* 2012;2:315. doi: 10.1038/srep00315
- 583 53. Peng CK, Havlin S, Stanley HE, Goldberger AL. Quantification of scaling
584 exponents and crossover phenomena in nonstationary heartbeat time series. *Chaos*
585 1995;5(1):82-7. doi: 10.1063/1.166141.
- 586 54. Downs SH, Black N. The feasibility of creating a checklist for the assessment of
587 the methodological quality both of randomised and non-randomised studies of health care
588 interventions. *J Epidemiol Community Health*. 1998;52(6):377-384. doi:
589 10.1136/jech.52.6.377.
- 590 55. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF.
591 Increased heart rate and reduced heart-rate variability are associated with subclinical
592 inflammation in middle-aged and elderly subjects with no apparent heart disease. *Eur*
593 *Heart J*. 2004;25(5):363-370. doi: 10.1016/j.ehj.2003.12.003.
- 594 56. Cooper TM, McKinley PS, Seeman TE, Choo TH, Lee S, Sloan RP. Heart Rate
595 Variability Predicts Levels of Inflammatory Markers: Evidence for the Vagal Anti-
596 Inflammatory Pathway. *Brain Behav Immun*. 2015;49:94-100. doi:
597 10.1016/j.bbi.2014.12.017.

- 598 57. Williams DP, Koenig J, Carnevali, Sgoifo A, Jarczok MN, Sternberg, et al. Heart
599 rate variability and inflammation: A meta-analysis of human studies. *Brain Behav*
600 *Immun.* 2019;80:219-226. doi: 10.1016/j.bbi.2019.03.009.
- 601 58. Parish RC, Todman S, Jain SK. Resting Heart Rate Variability, Inflammation, and
602 Insulin Resistance in Overweight and Obese Adolescents. *Metab Syndr Relat Disord.*
603 2016;14(6):291-297. doi: 10.1089/met.2015.0140
- 604 59. Poirier P, Hernandez TL, Weil KM, Shepard TJ, Eckel RH. Impact of diet induced
605 weight loss on the cardiac autonomic nervous system in severe obesity. *Obes. Res.* 2003;
606 11 (9), 1040–1047. <https://doi.org/10.1038/oby.2003.143>
- 607 60. Ito H, Ohshima A, Tsuzuki M, et al. Effects of increased physical activity and
608 mild calorie restriction on heart rate variability in obese women. *Jpn Heart*
609 *J* 2001; 42: 459- 469.
- 610 61. Nakano Y, Oshima T, Sasaki S, et al. Calorie restriction reduced blood pressure
611 in obesity hypertensives by improvement of autonomic nerve activity and insulin
612 sensitivity. *J Cardiovasc Pharmacol* 2001; **38** (Suppl 1): S69- S74.
- 613 62. Facchini M, Malfatto G, Sala L, et al. Changes of autonomic cardiac profile after
614 a 3-week integrated body weight reduction program in severely obese patients. *J*
615 *Endocrinol Investig* 2003;26: 138-142.
- 616 63. Costa J, Moreira A, Moreira P, Delgado L, Silva D. Effects of weight changes in
617 the autonomic nervous system: A systematic review and meta-analysis. *Clin Nutr.* 2019
618 Feb;38(1):110-126. doi: 10.1016/j.clnu.2018.01.006.
- 619 64. Adachi T, Sert-Kuniyoshi FH, Calvin AD, Singh P, Romero-Corral A, van der
620 Walt C, Davison DE, Bukartyk J, Konecny T, Pusalavidyasagar S, Sierra-Johnson J,
621 Somers VK. Effect of weight gain on cardiac autonomic control during wakefulness and
622 sleep. *Hypertension.* 2011 Apr;57(4):723-30. doi:
623 10.1161/HYPERTENSIONAHA.110.163147.

- 624 65. Akehi, Yuko; Yoshimatsu, Hironobu; Kurokawa, Mamoru; Sakata, Toshiie; Eto,
625 Hiroshi; Ito, Sukenobu; Ono, Junko (2001). *VLCD-Induced Weight Loss Improves Heart*
626 *Rate Variability in Moderately Obese Japanese. Experimental Biology and Medicine,*
627 *226(5), 440–445. doi:10.1177/153537020122600508*
- 628 66. Mager DE, Wan R, Brown M, et al. Caloric restriction and intermittent fasting
629 alter spectral measures of heart rate and blood pressure variability in rats. *FASEB J* 2006;
630 20: 631- 637.
- 631 67. Pontiroli AE, Merlotti C, Veronelli A, Lombardi F. Effect of weight loss on
632 sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus
633 hypocaloric diet. *Acta Diabetol* 2013; 50: 843- 850.
- 634 68. Martin J, Paquette C, Marceau S, Hould FS, Lebel S, Simard S, Dumesnil JG,
635 Poirier P. Impact of orlistat-induced weight loss on diastolic function and heart rate
636 variability in severely obese subjects with diabetes. *J Obes.* 2011;2011:394658. doi:
637 10.1155/2011/394658.
- 638 69. Sobocki J, Herman RM, Fraczek M. Occipital C1-C2 neuromodulation decreases
639 body mass and fat stores and modifies activity of the autonomic nervous system in
640 morbidly obese patients—a pilot study. *Obes Surg* 2013; 23: 693- 697.
- 641 70. Billman GE. The LF/HF ratio does not accurately measure cardiac sympatho-
642 vagal balance. *Frontiers in Physiology* 2013;4(26).
643 <http://doi.org/10.3389/fphys.2013.00026>
- 644 71. Reyes del Paso GA, Langewitz W, Mulder LJ, Roon A, Duschek S. The utility of
645 low frequency heart rate variability as an index of sympathetic cardiac tone: a review with
646 emphasis on a reanalysis of previous studies. *Psychophysiology* 2013;50(5):477-487.
- 647 72. Heathers JA. Sympathovagal balance from heart rate variability: an obituary.
648 *Experimental Physiology* 2012;97(4):556-556.

- 649 73. Goldstein DS, Benthon O, Park MY, Sharabi Y. Low-frequency power of heart rate
650 variability is not a measure of cardiac sympathetic tone but may be a measure of
651 modulation of cardiac autonomic outflows by baroreflexes. *Experimental Physiology*
652 2011;96(12):1255-1261.
- 653 74. Houle MS, Billman GE. Low-frequency component of the heart rate variability
654 spectrum: a poor marker of sympathetic activity. *American Journal of Physiology-Heart
655 and Circulatory Physiology* 1999;267:H215–H223
- 656 75. Eckberg DL. Sympathovagal balance: a critical appraisal. *Circulation* 1997;96:
657 3224–3232 10.1161/01.CIR.96.9.3224
- 658 76. Hopf HB, Skyschally A, Heusch G, Peters J. Low-frequency spectral power of
659 heart rate variability is not a specific marker of cardiac sympathetic modulation.
660 *Anesthesiology* 1995;82:609–619.
- 661 77. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL.
662 Et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two
663 community based studies. *J Clin Endocrinol Meta.* 2011;96(10):3242–9. doi:
664 10.1210/jc.2011-1182.
- 665 78. Algham MF, Lux TR, Leichman JG. et al. Progressive Regression of Left
666 Ventricular Hypertrophy Two Years After Bariatric Surgery. *Am J Med.*
667 2010;123(6):549-55. doi: 10.1016/j.amjmed.2009.11.020
- 668 79. Kaier TE, Morgan D, Grapsa J. et al. Ventricular remodelling post-bariatric
669 surgery: is the type of surgery relevant? A prospective study with 3D speckle tracking.
670 *European Heart Journal* 2014;15(11):1256-1262. <https://doi.org/10.1093/ehjci/jeu116>
- 671 80. Le Jemtel TH, Samson R, Jaiswal A, Lewine EB, Oparil S. Regression of Left
672 Ventricular Mass After Bariatric Surgery. *Curr Hypertens Rep.* 2017;19(9):68. doi:
673 10.1007/s11906-017-0767-5.
- 674

- 675 81. Kurajoh M, Koyama H, Kadoya M. et al. Plasma leptin level is associated with
676 cardiac autonomic dysfunction in patients with type 2 diabetes: HSCAA study.
677 *Cardiovasc Diabetol.* 2015;14:117. doi:10.1186/s12933-015-0280-6.
678
- 679 82. Varela L, Horvath TL. A sympathetic view on fat by leptin. *Cell* 2015;163: 26-
680 27. doi: 10.1016/j.cell.2015.09.016.
- 681 83. Zhang Y, Scarpace PJ. The role of leptin in leptin resistance and obesity.
682 *Physiology and Behavior* 2006;88(3):249-256. doi: 10.1016/j.physbeh.2006.05.038.
- 683 84. Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin
684 resistance: underlying mechanisms and diagnosis. *Diabetes Metab Syndr Obes.*
685 2019;12:191-198. doi: 10.2147/DMSO.S182406.
686
- 687 85. Abrahamsson N, Engström B, Sundbom M, Karlsson FA. Gastric bypass surgery
688 elevates NT-ProBNP levels. *Obes Surg.* 2013;23(9):1421–6. doi: 10.1007/s11695-013-
689 0889-z
690
- 691 86. Martin J, Bergeron S, Pibarot P. et al. Impact of bariatric surgery on N-terminal
692 fragment of the prohormone brain natriuretic peptide and left ventricular diastolic
693 function. *Can J Cardiol.* 2013;29(8):969–75. doi: 10.1016/j.cjca.2012.11.010
694
- 695 87. Pereira-Barreto AC, Oliveira Junior MT, Strunz CC, Del Carlo CH, Scipioni AR,
696 Ramires JAF. Serum NT-proBNP Levels are a Prognostic Predictor in Patients with
697 Advanced Heart Failure. *Arq Bras Cardiol.* 2006;87(2):174-177. doi: 10.1590/s0066-
698 782x2006001500016.
699
700

701 **FIGURE LEGENDS**

702

703 Figure 1. Flow diagram of the Prisma protocol with search process and selection steps.

704

705

706

707 **TABLE LEGENDS**

708

709 Table 1. Description of the selected articles by author and year, study design, sample, age
710 (years), BMI (kg/m²), intervention, mensuration, HRV indexes, key results and
711 confidence interval.

712

713 Table 2. Evaluation of the Downs and Black Checklist for Quality Assessment.

714

715 Table 3. Illustration of the deviations in the follow-up period after bariatric procedure.

716

717

718

719

Table 1. Description of the selected articles by author and year, study design, sample, age (years), BMI (kg/m²), intervention, mensuration, HRV indexes, key results and confidence interval.

| <i>Author</i> | <i>Study Design</i> | <i>Sample</i> | <i>Age (years)</i> | <i>BMI (kg/m²)</i> | <i>Intervention</i> | <i>Follow-Up (After and before surgery)</i> | <i>HRV indexes</i> | <i>Key results</i> |
|---------------------------------|---------------------------------|--|---|--|---------------------|---|---|---|
| Lips et al. ³⁸ | Non-randomized controlled trial | 65 women: 11 Grupo controle; 27 Obesos with NGT 27 Obesos with TDM2 | Control Group: 49,4±0,6 Obese NGT: 47,7± 6,4 Obese TDM2: 51,0±7.1 | Control Group: 21,7±1.6 Obese NGT: 43,8±3.2 Obese TDM2: 42,0±5.5 | RGB, AGB and VLCD | Preoperative Post-operative (3th week e 3 month) | Mean RR, RMSSD, SD1, SD2, SD1/SD2 | RYGB and VLCD promotes optimization on control of vagal heart rhythm within 3 weeks in patients with DM2. After 3 months, the increase in HRV was evident in other groups, except in the NGT group. |
| Gandolfini et al. ³⁵ | Prospective cohort study | 32 women and 2 men | 36 ± 11 | 46,3± 5,9 | RGB | Preoperative Post-operative (12th month) | HR (bpm), SDNN | A significant increase was observed in the SDNN index at 12 months after surgery, indicating an improvement in HRV. |
| Wu et al. ³⁶ | Prospective cohort study | 9 women and 9 man | 34 ± 10,2 | 45,4±6,8 | VSG | Preoperative Post-operative (7th, 30th, 90th e 180th days) | Mean RR, SDNN, SDANN, RMSSD, pNN50, VLF, HF, LF, LF/HF, SD1 e SD2 | Improvements in insulin resistance were associated with increases in the RMSSD and HF indices. |
| Maser et al. ³⁷ | Prospective cohort study | 29 women and 3 man | 38 ± 11 | 51 ± 11 | RGB | Preoperative Post-operative (6th month) | LF(ms ²), LF(nu), HF(ms ²), HF(nu), LF/HF | The induced weight loss provided an improvement in cardiac autonomic control, identified through the spectral activity of HRV indices. |

| | | | | | | | | |
|--------------------------------------|---------------------------------|---|--|---|--------|--|--|---|
| Braga et al. ³² | Prospective cohort study | Medical Treatment: 16 women and 4 man Surgical Group: 14 women and 6 man | Medical Treatment: 35 ± 11,7 Surgical Group: 38,5± 10,6 | Medical Treatment: 42,9± 4,7 Surgical Group: 41,5± 5,0 | RGB | Preoperative Post-operative (3th month) | SDNN, RMSSD, PNN50, NN50, LF, HF, LF/HF | Three months after bariatric surgery, the increase in HRV was identified through the time domain indexes. |
| Lucas et al. ³³ | Prospective cohort study | 26 women and 2 men | 42,6± 11,6 | 44,1± 6,3 | RGB | Preoperative Post-operative (3th and 6 months) | HR(bpm), RR mean, SDNN, rMSSD, NN50, pNN50% | It was identified improving vagal cardiac control in three and six months, after a BS. |
| Nault et al. ⁴⁴ | Non-randomized controlled trial | 6 women and 4 men | Surgical Group :37,7± 8,5 Control Group: 44,7± 10,8 | Surgical Group: 52,3± 7,6 Control Group: 54,3± 10,9 | BPD-DS | Preoperative Post-operative (between 6th- 12th month) | HR(bpm), SDNN, SDANN, RMSSD, PNN50, LF(ms2), HF (ms2), LF/HF (ms2) | After BS there was an increase in HRV indices and a decrease in HR. |
| Machado et al. ⁴³ | Prospective cohort study | 42 women and 19 men | 37 (18-66) | 43 (37- 56) | RGB | Preoperative Post-operative (6th month) | RR, SDNN, RMSSD, PNN50% | There was an increase in HRV after surgery, both in the total variability (NN, SDNN) and in the short-term components of HRV (PNN50 and RMSSD). |
| Bobbioni-Harsch et al. ⁴¹ | Prospective cohort study | 12 women | Operation: 39,5 ± 2 Control Group: 40,0 ± 2 | Operation: 44,6 ± 1.1 Control Group: 29,7 ± 1.6 | RGB | Preoperative Post-operative (3th and 12th month) | SDNN (ms), HRVi, TINN (ms), pNN50%. | Improvements in HRV indices were seen most robustly in the 12 months after surgery. |

| | | | | | | | | |
|------------------------|--------------------------|---------------------------------|--|---|-----------|--|---|---|
| Alam et al. 42 | Prospective cohort study | 8 women and 3 men | 47.8±7.9 | 48.2±6.9 | AGB, BPD | Preoperative Post-operative (1st, 6th, 12th month) | HR(bpm), RMSSD, SDNN, SampEn, DFAa-NN, | Some indexes showed changes from 1 month after the surgical procedure. In the more longitudinal analyzes, changes were seen in a greater number of indices. |
| Perugini et al. 40 | Prospective cohort study | 21 women and 7 men | 45±9.0 | 46±6.0 | RGB | Preoperative Post-operative (2nd week e 6th month) | HR(bpm), RMSSD, SDNN, SDANN and HRVi. | HRV optimization was identified in a short period (two weeks), as well as in a period of six months after the intervention. |
| Casellini et al. 34 | Prospective cohort study | 57 women and 13 men | Non-DM: 41.23±2.36 Pre-DM: 39.71±2.20 T2DM: 52.252±2.41 | Non-DM: 46.75±1.39 Pre-DM: 46.99±1.34 T2DM: 44.18±1.52 | RGB, SVG | Preoperative Post-operative (4th, 12th and 24th week) | HR(bpm), RMSSD, SDNN | The increase in HRV after BS was more evident in patients with TDM2. |
| Ibache et al. | Prospective cohort study | 23 women | 36.0 ± 11.1 | 35.1 ± 3.4 | SVG | Preoperative Post-operative (1st and 3rd month) | HR(bpm), RMSSD, SDNN, PNN50, HF, LF, LF/HF, SD1, SD2 and SampEn | There was an improvement in HRV parameters at one and three months after the BS procedure. |
| Kokkinos et al. | Prospective cohort study | 37 patients (sex non-specified) | RYGB: 38.0±7.8 SVG: 40.3±9.9 | RYGB: 47.9±6.0 SVG: 51.6±7.5 | RYGB, SVG | Preoperative Post-operative (3rd and 6th month) | HF, LF/ LF/HF | The RYGB and SVG procedures have the same results in the HRV parameters after the BS procedure. |

AGB= Adjustable Gastric Banding; RGB= Roux-en-Y gastric by-pass; BPD= Biliopancreatic Diversion; BPD-DS= Biliopancreatic Diversion with a Duodenal Switch; VSG= Vertical Sleeve Gastrectomy; NGT= Normal glucose tolerance; TDM2= Type 2 diabetes mellitus; VLCD= Very low caloric diet; RR= RR intervals; HR= Heart Rate; bpm= Beat per minute; Min= minimum; Max= maximum; RMSSD = square root of the differences between adjacent normal RR intervals; SDNN = standard deviation of all normal RR intervals; SDANN= standard deviation of averaged RR intervals over a 5-minute period; pNN50 = percentage of adjacent RR intervals with duration difference greater than 50ms; HRVi= triangular index calculated from the total number of all RR intervals divided by the height of the histogram of all RR


intervals; TINN= Triangular Interpolation of RR intervals histogram LF = low frequency component; HF = high frequency component; VLF= very low frequency component; LF / HF = ratio between low and high frequency components; Nu: standard unit; ms²: absolute unit; SD1: dispersion of points perpendicular to the identity line, instantaneous record of beat-to-beat variability; SD2: scatter of points along the identity line; long-term record of HRV; SampEN= Sample entropy; DFAa (NN)= Detrended fluctuation fractal analysis of NN intervals;

Downs & Black - Checklist Items

| Study | Year | Reporting | | | External Validity | | Bias | Counfounding | | Power | Quality Rating |
|--------------------------------------|------|-----------|----------|----------|-------------------|----|------|--------------|--|-------|----------------|
| | | 1 to 10 | 11 to 13 | 13 to 20 | 21 to 26 | 27 | | Total | | | |
| Lips et al. ³⁸ | 2013 | 10 | 2 | 5 | 3 | 1 | 21 | | | | |
| Gandolfini et al. ³⁵ | 2015 | 9 | 2 | 4 | 3 | 1 | 19 | | | | |
| Wu et al. ³⁶ | 2014 | 9 | 2 | 4 | 3 | 1 | 19 | | | | |
| Maser et al. ³⁷ | 2013 | 8 | 2 | 4 | 3 | 1 | 18 | | | | |
| Braga et al. ³² | 2020 | 10 | 2 | 4 | 4 | 1 | 21 | | | | |
| Lucas et al. ³³ | 2020 | 10 | 3 | 5 | 4 | 1 | 23 | | | | |
| Nault et al. ⁴⁴ | 2006 | 9 | 2 | 5 | 1 | 1 | 18 | | | | |
| Machado et al. ⁴³ | 2009 | 9 | 2 | 4 | 4 | 1 | 20 | | | | |
| Bobbioni-Harsch et al. ⁴¹ | 2009 | 9 | 2 | 4 | 3 | 1 | 19 | | | | |
| Alam et al. ⁴² | 2009 | 8 | 2 | 5 | 1 | 1 | 17 | | | | |
| Perugini et al. ⁴⁰ | 2010 | 8 | 2 | 5 | 2 | 1 | 18 | | | | |
| Casellini et al. ³⁴ | 2016 | 10 | 2 | 5 | 2 | 1 | 20 | | | | |
| Ibacache et al. | 2020 | 9 | 2 | 5 | 3 | 1 | 20 | | | | |
| Kokkinos et al. | 2013 | 9 | 2 | 4 | 4 | 1 | 20 | | | | |



PRISMA 2009 Flow Diagram



- The studies present heterogeneity regarding the HRV measurement intervals during follow-up after BS;
- There was an increase in parasympathetic HR control and HRV and, a decrease in HR in all BS methods undertaken;
- The literature does not provide evidence that this effect was directly caused by the surgical procedure;
- Few studies have demonstrated that BS encouraged an earlier and more evident restoration of cardiac autonomic control in patients with T2DM;
- The decrease in insulin resistance was correlated with the increase in HRV in some studies, but, other studies are unresponsive of these outcomes;
- Improvements in metabolic parameters (e.g., Leptin, NT-proBNP) were positively correlated with an increase in HRV